Stockscreener 앱 받기
9.59
1.44%
-0.14
시간 외 거래:
9.59
전일 마감가:
$9.73
열려 있는:
$9.65
하루 거래량:
254.18K
Relative Volume:
1.33
시가총액:
$471.58M
수익:
$62.02M
순이익/손실:
$-45.65M
주가수익비율:
0.8442
EPS:
11.36
순현금흐름:
$-9.60M
1주 성능:
-2.94%
1개월 성능:
-3.81%
6개월 성능:
+10.74%
1년 성능:
-12.58%
1일 변동 폭
$9.56
$9.83
1주일 범위
$9.56
$10.08
52주 변동 폭
$7.44
$11.71
Theravance Biopharma Inc Stock (TBPH) Company Profile
명칭
Theravance Biopharma Inc
전화
650-808-6000
주소
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
TBPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
9.59 | 471.58M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | 개시 | BTIG Research | Buy |
| 2024-01-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-15 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-08-25 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | 개시 | JP Morgan | Overweight |
| 2020-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-05-13 | 개시 | Cowen | Outperform |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-06 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | 개시 | H.C. Wainwright | Buy |
| 2018-03-29 | 재개 | Piper Jaffray | Overweight |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-05-11 | 재확인 | Needham | Buy |
| 2016-12-21 | 개시 | Needham | Buy |
| 2016-11-03 | 개시 | Piper Jaffray | Overweight |
| 2016-10-12 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | 개시 | Guggenheim | Buy |
| 2016-06-20 | 재확인 | Leerink Partners | Outperform |
| 2016-05-12 | 개시 | Leerink Partners | Outperform |
| 2016-05-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
모두보기
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 21,372 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Wellington Management Group LLP Sells 159,258 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
When (TBPH) Moves Investors should Listen - Stock Traders Daily
Theravance Biopharma to Meet Investors at J.P. Morgan Healthcare Conference 2025 - StockTitan
Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue? - MSN
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance
Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics - The Globe and Mail
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
What is Zacks Research's Estimate for TBPH FY2024 Earnings? - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Acquired by BNP Paribas Financial Markets - MarketBeat
(TBPH) Trading Advice - Stock Traders Daily
Theravance Biopharma (STU:0TB) Shares Outstanding (EOP) : 49.17 Mil (As of Sep. 2024) - GuruFocus.com
105,609 Shares in Theravance Biopharma, Inc. (NASDAQ:TBPH) Bought by Algert Global LLC - MarketBeat
Trading (TBPH) With Integrated Risk Controls - Stock Traders Daily
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizentribune
Theravance Biopharma to Present at Evercore HealthCONx Conference | TBPH Stock News - StockTitan
Baupost's top Q3 trades include Jazz exit, new Dollar General stake - MSN
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates - MSN
(TBPH) Investment Report - Stock Traders Daily
Theravance Biopharma Inc (TBPH) Quarterly 10-Q Report - Quartzy
Madison Avenue Partners, LP Expands Stake in Theravance Biopharm - GuruFocus.com
Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat
Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares - Investing.com India
Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com - Investing.com Canada
Earnings call: Theravance Biopharma reports growth in Q3 2024 - Investing.com
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript - Insider Monkey
Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Initiatives - GuruFocus.com
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Theravance Biopharma’s Third Quarter 2024 Financial Insights - TipRanks
Theravance Biopharma Q3 2024 Earnings: Revenue Surpasses Estimat - GuruFocus.com
Theravance Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For - Simply Wall St
What To Expect From Theravance Biopharma Inc (TBPH) Q3 2024 Earnings - GuruFocus.com
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
Theravance Biopharma (TBPH) Scheduled to Post Earnings on Tuesday - Defense World
5 Small Drug Stocks to Buy as Trump Gets Re-Elected - Yahoo Finance
Theravance Biopharma (TBPH) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Theravance Biophar - GuruFocus.com
(TBPH) Proactive Strategies - Stock Traders Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by SG Americas Securities LLC - MarketBeat
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 - StockTitan
Q3 EPS Estimate for Theravance Biopharma Boosted by Analyst - MarketBeat
Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - Defense World
What is Zacks Research's Estimate for TBPH Q4 Earnings? - MarketBeat
Theravance Biopharma Inc (TBPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Theravance Biopharma Inc 주식 (TBPH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Samaha Eli | 10% Owner |
Aug 07 '24 |
Buy |
7.80 |
999,800 |
7,798,440 |
9,511,150 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Jul 10 '24 |
Sale |
9.00 |
4,000 |
36,000 |
335,965 |
| Samaha Eli | 10% Owner |
May 01 '24 |
Buy |
8.75 |
1,499,124 |
13,117,335 |
8,511,350 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Feb 22 '24 |
Sale |
8.71 |
1,254 |
10,922 |
311,733 |
2.88%
2.65%
자본화:
|
볼륨(24시간):